Opportunity Information: Apply for PAR 14 285
Apply for PAR 14 285
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN) (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Jul 17, 2014 and posted on Jul 17, 2014.
- Applicants must submit their applications by Apr 14, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $450,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments City or township governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Special district governments County governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Innovative Research in Cancer Nanotechnology (IRCN) (U01) funding opportunity (PAR-14-285) is a National Institutes of Health, National Cancer Institute (NCI) cooperative agreement designed to support ambitious, multidisciplinary projects that use nanotechnology to drive meaningful advances in cancer biology and oncology. It sits within the larger NCI Alliance for Nanotechnology in Cancer program, which aims to accelerate cancer-relevant nanoscience and translate fundamental discoveries into approaches that can improve how cancer is understood, detected, and treated. The core idea behind this FOA is to fund research that is not simply incremental, but genuinely innovative and potentially transformative, especially where nanotechnology can help overcome well-known bottlenecks or limitations in current cancer research and clinical strategies.
A central emphasis of the announcement is on tackling major barriers in cancer through nanotechnology with a strong grounding in fundamentals. Proposed projects are expected to go beyond building a new nanoparticle or platform and instead clarify how nanomaterials interact with biological systems or how they can be delivered effectively in living organisms. That includes, for example, understanding nano-bio interactions at the molecular, cellular, tissue, and whole-body levels; identifying mechanisms that govern distribution, targeting, uptake, clearance, toxicity, or immune interactions; and developing delivery strategies that address real in vivo challenges such as tumor heterogeneity, vascular barriers, the tumor microenvironment, and off-target accumulation. In other words, the FOA signals that strong applications will connect nanotechnology design to biological mechanism and demonstrate why the nano-enabled approach is positioned to break through a cancer-relevant obstacle.
The award mechanism is a U01 cooperative agreement, which generally indicates substantial programmatic involvement from NIH/NCI staff compared with a standard research grant. While the scientific direction remains driven by the awardee, cooperative agreements typically involve active coordination, shared milestones, and collaboration expectations consistent with being part of a broader NCI initiative. This structure is meant to support complex, team-based research where coordination and alignment with program goals can accelerate progress and dissemination.
From an applicant standpoint, eligibility is broad and includes many types of U.S. organizations and governments, such as public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (including small businesses), school districts, and a range of local, county, state, tribal, and special district governments. The FOA also explicitly allows non-U.S. entities to apply, including foreign organizations and foreign institutions, and it allows foreign components of U.S. organizations as defined under NIH policy. It also highlights eligibility for a variety of mission-driven and capacity-building institution types, including HBCUs, Hispanic-serving institutions, AANAPISIs, TCCUs, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others. There is no cost sharing or matching requirement noted for this opportunity.
In terms of topic alignment, the FOA is categorized under health and connects to multiple cancer research areas reflected in the CFDA program listings: cancer cause and prevention research (93.393), cancer detection and diagnosis research (93.394), cancer treatment research (93.395), and cancer biology research (93.396). That spread signals that nanotechnology projects can be proposed across the cancer research continuum as long as they address significant barriers and provide mechanistic insight related to nanomaterial behavior and/or in vivo delivery.
On funding and timing, the opportunity listed an estimated total funding amount of $450,000 with an award ceiling of $450,000 (as presented in the source data provided). The FOA was posted on July 17, 2014, and ultimately closed on April 14, 2017, with an archive date of May 15, 2017. The announcement also notes that NCI planned a pre-application informational webinar, with details to be posted through the NCI nanotechnology program website, reflecting the agency’s intent to help prospective applicants understand program priorities and submission expectations.
For further details, the full FOA was made available through the NIH Grants Guide (linked in the announcement materials), and NIH’s Office of Extramural Research (OER) provides support contacts for access and linking issues. Overall, the IRCN (U01) opportunity was positioned as a team-science, mechanism-driven nanotechnology research program focused on unlocking new capabilities in cancer research by deeply understanding and controlling how nanomaterials behave in complex biological environments.
Frequently Asked Questions (FAQs)
What is the Innovative Research in Cancer Nanotechnology (IRCN) (U01) opportunity?
IRCN (U01) (PAR-14-285) is a National Institutes of Health (NIH), National Cancer Institute (NCI) cooperative agreement funding opportunity designed to support ambitious, multidisciplinary research projects that use nanotechnology to produce meaningful advances in cancer biology and oncology.
Which NIH institute is sponsoring this funding opportunity?
The opportunity is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
How does this opportunity fit within NCI programs?
It sits within the larger NCI Alliance for Nanotechnology in Cancer program, which focuses on accelerating cancer-relevant nanoscience and translating fundamental discoveries into approaches that can improve how cancer is understood, detected, and treated.
What is the main goal of the FOA?
The FOA aims to fund research that is genuinely innovative and potentially transformative (not incremental), particularly where nanotechnology can overcome well-known bottlenecks or limitations in current cancer research and clinical strategies.
What kinds of projects are strongly emphasized?
The announcement emphasizes projects that tackle major cancer barriers through nanotechnology with a strong grounding in fundamentals. Proposals are expected to connect nanotechnology design to biological mechanism and explain why the nano-enabled approach is positioned to break through a cancer-relevant obstacle.
Is this FOA mainly about creating new nanoparticles or platforms?
No. The FOA signals that strong applications should go beyond simply building a new nanoparticle or platform. Projects should clarify how nanomaterials interact with biological systems and/or how they can be delivered effectively in living organisms.
What types of nano-bio interaction questions does the FOA highlight?
The FOA highlights understanding nano-bio interactions across multiple biological scales, including molecular, cellular, tissue, and whole-body levels.
What specific mechanisms related to nanomaterials are called out as important?
Examples listed include mechanisms governing distribution, targeting, uptake, clearance, toxicity, and immune interactions.
What in vivo delivery challenges does the FOA explicitly mention?
The FOA points to real in vivo barriers such as tumor heterogeneity, vascular barriers, the tumor microenvironment, and off-target accumulation.
What is the award mechanism for this opportunity?
The mechanism is a U01 cooperative agreement.
What does a U01 cooperative agreement imply about NIH/NCI involvement?
A U01 generally indicates substantial programmatic involvement from NIH/NCI staff compared with a standard research grant. While the scientific direction remains driven by the awardee, the structure typically involves active coordination, shared milestones, and collaboration expectations consistent with participation in a broader NCI initiative.
Why does the FOA use a cooperative agreement structure?
This structure is intended to support complex, team-based research where coordination and alignment with program goals can accelerate progress and dissemination.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and governments, such as public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations (including small businesses), school districts, and local/county/state/tribal/special district governments.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA explicitly allows non-U.S. entities to apply, including foreign organizations and foreign institutions. It also allows foreign components of U.S. organizations as defined under NIH policy.
Does the FOA encourage applications from specific institution types?
It highlights eligibility for various mission-driven and capacity-building institution types, including HBCUs, Hispanic-serving institutions, AANAPISIs, TCCUs, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others.
Is cost sharing or matching required?
No cost sharing or matching requirement is noted for this opportunity.
What broad research areas does this FOA connect to?
The FOA is categorized under health and aligns with multiple cancer research areas across the continuum, including cancer cause and prevention, detection and diagnosis, treatment, and cancer biology, as long as projects address significant barriers and provide mechanistic insight related to nanomaterial behavior and/or in vivo delivery.
Which CFDA program areas are referenced?
The announcement references CFDA listings: 93.393 (cancer cause and prevention research), 93.394 (cancer detection and diagnosis research), 93.395 (cancer treatment research), and 93.396 (cancer biology research).
How much funding is available under the opportunity (as listed in the provided information)?
The opportunity listed an estimated total funding amount of $450,000 with an award ceiling of $450,000 (as presented in the source data provided).
When was the FOA posted and when did it close?
The FOA was posted on July 17, 2014, and closed on April 14, 2017.
When was the opportunity archived?
The archive date was May 15, 2017.
Was there any pre-application webinar or informational event mentioned?
Yes. The announcement notes that NCI planned a pre-application informational webinar, with details to be posted through the NCI nanotechnology program website.
Where can applicants find the full FOA text?
The full FOA was made available through the NIH Grants Guide (linked in the announcement materials).
Where can someone get help with access or linking issues related to the FOA?
NIH's Office of Extramural Research (OER) provides support contacts for access and linking issues.
What overall research approach is this FOA trying to promote?
Overall, the IRCN (U01) opportunity was positioned as a team-science, mechanism-driven nanotechnology research program focused on unlocking new capabilities in cancer research by deeply understanding and controlling how nanomaterials behave in complex biological environments.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: COMMUNITY FIRE ASSISTANCE WILDLAND FIRE RELATED PROJECTS
Previous opportunity: White Clay Creek Management Plan Implementation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 285
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 285) also looked into and applied for these:
| Funding Opportunity |
|---|
| Centers of Cancer Nanotechnology Excellence (CCNEs) (U54) Apply for RFA CA 14 013 Funding Number: RFA CA 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College Attending Youth (U01) Apply for RFA DA 15 010 Funding Number: RFA DA 15 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Arts Based Approaches in Palliative Care for Symptom Management (R01) Apply for PAR 14 294 Funding Number: PAR 14 294 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01) Apply for RFA CA 14 012 Funding Number: RFA CA 14 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Approaches to Synthetic Lethality for Mutant KRas Dependent Cancers (U01) Apply for PAR 14 314 Funding Number: PAR 14 314 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Obesity and Asthma Awareness and Self Management (R01) Apply for PA 14 316 Funding Number: PA 14 316 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition AIDS Malignancy Clinical Trials Consortium (UM1) Apply for RFA CA 14 502 Funding Number: RFA CA 14 502 Agency: National Institutes of Health Category: Education Health Funding Amount: $21,400,000 |
| Developing Interventions for Health Enhancing Physical Activity (R21/R33) Apply for PAR 14 321 Funding Number: PAR 14 321 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Training Modules to Enhance Data Reproducibility (R25) Apply for RFA GM 15 006 Funding Number: RFA GM 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Limited Competition International Agency for Research on Cancer (IARC) Monographs Program (U01) Apply for RFA CA 14 503 Funding Number: RFA CA 14 503 Agency: National Institutes of Health Category: Education Health Funding Amount: $859,000 |
| Advancing Interventions to Improve Medication Adherence (R21) Apply for PA 14 335 Funding Number: PA 14 335 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 14 339 Funding Number: PAR 14 339 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Self Management for Health in Chronic Conditions (R01) Apply for PA 14 344 Funding Number: PA 14 344 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Self Management for Health in Chronic Conditions (R21) Apply for PA 14 343 Funding Number: PA 14 343 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Self Management for Health in Chronic Conditions (R15) Apply for PA 14 345 Funding Number: PA 14 345 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2015 and 2016 (P50) Apply for PAR 14 353 Funding Number: PAR 14 353 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,300,000 |
| Epidemiology of Drug Abuse (R01) Apply for PA 15 003 Funding Number: PA 15 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epidemiology of Drug Abuse (R03) Apply for PA 15 002 Funding Number: PA 15 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Epidemiology of Drug Abuse (R21) Apply for PA 15 001 Funding Number: PA 15 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Office of American Schools and Hospitals Abroad (ASHA) Fiscal Year 2015 Program Apply for APS ASHA 15 000001 Funding Number: APS ASHA 15 000001 Agency: Agency for International Development Category: Education Health Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 285", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.